الفهرس 
Incidence:Only 14 pages are availabe for public view
 |  | from | 171 |  |  |
| | | from | 171 | | |
Abstract
Background: Cetuximab which is a monoclonal antibody can be added to folfox regimen in treatment of patients with RAS wild metastatic cancer colon and this may improve the progression free survival and overall survival of these patients. We investigated the efficacy of cetuximab plus oxaliplatin, fluorouracil, and leucovorin (FOLFOX) as first-line treatment for metastatic colorectal cancer.
Objective: To retrospective analyses of progression-free survival, overall survival, overall response rate, resectability and safety within the different patient populations with metastatic cancer colon treated by cetuximab plus FOLFOX versus FOLFOX alone.
Patients and Methods: A Retrospective controlled trial study, 100 patients were selected to participate in our study based on our inclusion criteria. They were recruited from Ain shams University Teaching Hospital and Alexandria Military Hospital, from January 2012 to December 2016.
Results: The initial treatment of metastatic colorectal cancer with a combination of Cetuximab plus FOLFOX, as compared with FOLFOX alone, reduced the risk of disease progression by 33.4% and also increased the response rate by nearly 13%. There was significant difference between the treatment groups in overall survival by 39%.
Conclusion: First-line treatment with cetuximab plus FOLFOX, as compared with FOLFOX alone, reduced the risk of progression of metastatic colorectal ca